PharmaFocus Today – Page 152 – media

Baumer 50 series process sensors lead the industry to new standards

In today’s rapidly accelerating industrial automation process, the performance and quality of process sensors play a crucial role in the precision, efficiency, and reliability of production. The newly launched 50 series process sensors by Bao Meng have numerous unique advantages, making them stand out among many similar products and once again attracting industry attention. The Baumer 50 series process sensors embody cutting-edge technology and innovative design concepts, with many outstanding features such as compact design, excellent performance, and easy operation. This series of high-performance sensors adheres to the consistent style of Baumer products, adopting a simple and unified operation mode, allowing operators to quickly and conveniently complete debugging work and easily get started in the subsequent use process. It covers the market tested PAC50 conductivity sensor, as well as the newly developed PT55 temperature sensor and PP56 pressure sensor. PP56 pressure sensor The PP56 pressure sensor has demonstrated an ...
- Source: drugdu
- 269
- December 7, 2024
47% more weight loss! Eli Lilly releases “single challenge” semaglutide data

On December 4, local time, Eli Lilly announced the results of the Phase 3b clinical study of SURMOUNT-5. The subjects in the weight loss version of Zepbound lost 50.3 pounds (22.8 kg) at week 72, and the subjects in the weight loss version of Wegovy lost 33.1 pounds (15 kg) during the same period. Compared with semaglutide, the average weight loss effect of Zepbound is 47% higher. SURMOUNT-5 is a multicenter, randomized, open-label, head-to-head study designed to evaluate the efficacy and safety of Zepbound and semaglutide in obese or overweight adults with at least one comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, and without diabetes. A total of 751 participants were recruited in the trial and assigned in a 1:1 ratio to receive the maximum tolerated dose of tirpotide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg). At 72 weeks, the average weight loss ...
- Source: https://mp.weixin.qq.com/
- 526
- December 7, 2024
1 “Parkinson’s new drug” approved for marketing

According to the official website of NMPA, Zambon/Parexel Pharmaceuticals’ Safinamide Mesylate Tablets have been approved for marketing. According to public information, Safinamide is a drug used to treat Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disease and a common activity disorder. Its main cause is a lack of dopamine. According to statistics, about 1-2% of people over 65 years old suffer from Parkinson’s disease worldwide. In China, there are more than 3 million Parkinson’s disease patients, and the incidence rate increases with age. It is predicted that the number of Parkinson’s patients in China will exceed 5 million in 2030. The “OFF” period is a common phenomenon in the middle and late stages of Parkinson’s disease. Patients usually show severe aggravation of symptoms such as muscle stiffness, tremor and movement difficulties. According to statistics, about 75% of Parkinson’s patients in the middle and late stages will ...
- Source: https://news.yaozh.com/archive/44631.html
- 421
- December 7, 2024
A local pharmaceutical company’s road to overtaking on a curve

At the end of 2011, the first drug of ranibizumab entered the Chinese market. As a biological drug for the treatment of fundus macular degeneration, it has a monopoly advantage in the market and is priced at nearly 10,000 yuan per bottle. Originally, multinational pharmaceutical companies wanted to make a fortune from this star product in the huge Chinese market, but no one could have imagined that a Chinese local company that “sticks to its research and development” – Kanghong Pharmaceutical would overtake others and bring down the price of the drug in one fell swoop… A pioneering journey of “a narrow escape from death” In 1994, Kanghong was established in the wave of reform and opening up. This innovative pharmaceutical company started with traditional Chinese medicine. Its Songling Xuemaikang Capsule is an exclusive patented Chinese medicine for the treatment of hypertension and primary hyperlipidemia. At the same time, in ...
- Source: https://news.yaozh.com/archive/44633.html
- 504
- December 7, 2024
Siemens Healthineers collaborates with the ‘Third Party Imaging Leader’

On December 1st, Siemens Healthineers and DeepHealth officially announced a major strategic partnership, with the latter partnering with Siemens Healthineers to implement SmartTechnology by embedding AI driven health informatics into workflows and imaging hardware ™， Bringing innovative changes to the field of ultrasound operations. Data shows that DeepHealth is a wholly-owned subsidiary of RadNet, a global leader in AI driven health informatics, dedicated to providing AI driven health informatics to achieve breakthroughs in the nursing field through imaging. RadNet is also the largest third-party independent medical imaging company in the United States. 01. DeepHealth collaborates with Siemens Healthineers At present, the high-capacity ultrasound nursing environment is facing severe challenges such as labor shortage, operator limitations and fatigue, and unstable image acquisition quality. These problems may not only delay accurate diagnosis, but also lead to unnecessary examination processes. In response to this situation, the remote collaboration and image acquisition command center ...
- Source: drugdu
- 309
- December 6, 2024
Toshiba to lay off another 3000 employees

Recently, according to authoritative financial media such as Kyodo News, legendary giant Toshiba is planning to implement a large-scale layoff in Japan, with an expected number of layoffs exceeding 3000, accounting for about 5% of its total Japanese employees. Toshiba further stated that this round of layoffs will mainly target employees aged 50 and above, and will be carried out through voluntary resignation. For employees who choose to resign before the end of November this year, the company will provide additional severance pay and promise to provide a two-year re employment support service to alleviate their worries. It is worth noting that this is not the first time Toshiba has taken large-scale layoffs this year. As early as May this year, Toshiba announced that it would lay off up to 5000 employees in Japan, accounting for about 6%, with the aim of accelerating the restructuring process and reducing costs to ...
- Source: drugdu
- 211
- December 6, 2024
Oncology field blossoms

On November 27, Huadong Medicine announced that its Sometuximab Injection and Rilonacept for Injection were approved for marketing by NMPA. On the same day, the drug registration and marketing authorization application for CD19 CAR-T candidate IM19 chimeric antigen receptor T cell injection (hereinafter referred to as “IM19”) was also accepted by NMPA. Sometuximab Injection (ELAHERE®/ELAHERE®) is used for the indication of folate receptor α-positive platinum-resistant ovarian cancer (PROC) that has received 1-3 lines of systemic treatment in the past; Rilonacept for Injection (trade name: Yanduo®/ARCALYST®) is used to treat cold pyrine-associated periodic syndrome (CAPS) in adults and adolescents aged 12 years and above, including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). Suomitoximab is a drug targeting FRα targets and is the only platinum-resistant recurrent ovarian cancer treatment drug on the market in the world. According to public information, Suomitoximab can recognize target proteins on the surface of tumor ...
- Source: drugdu
- 186
- December 6, 2024
Novo Nordisk’s “GIP/GLP-1 dual agonist” has been approved for clinical trials in China

According to the CDE official website, Novo Nordisk’s Class 1 new drug NNC0519-0130 injection has obtained implicit approval for clinical trials, and its indication is type 2 diabetes. According to public information, the drug is a GIP/GLP-1 dual agonist. GIP and GLP-1 are two important hormones that regulate blood sugar. The function of GLP-1 is to stimulate insulin secretion and inhibit glucagon secretion; GIP is a dual-function hormone that promotes insulin secretion in high blood sugar and stimulates the release of glucagon in low blood sugar to stabilize blood sugar. Studies have shown that GIP can reduce food intake and increase energy consumption, thereby reducing weight. When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on glucose levels and body weight. According to the ClinicalTrials website, Novo Nordisk has launched multiple clinical studies on NNC0519-0130 injection in many places around the world, including ...
- Source: drugdu
- 276
- December 6, 2024
Employee sentenced to 13 years in prison, AstraZeneca insurance fraud storm is not over

From June to September 2024, many cases related to AstraZeneca insurance fraud were sentenced one after another. An operation named “Star Project” by the prosecutor revealed the tip of the iceberg of pharmaceutical representatives tampering with genetic test reports and defrauding medical insurance funds. AstraZeneca, the fastest growing British multinational pharmaceutical company in China and the most watched “sales champion” in the pharmaceutical industry, was exposed to be involved in many “insurance fraud cases”. According to the criminal verdicts obtained by the reporter, in the past three years, there have been many AstraZeneca “insurance fraud cases” that have been tried or sentenced in Shenzhen and Fujian alone, and there are also cases waiting to be heard in Chongqing and Jiangxi. Some people in the pharmaceutical industry pointed out that the AstraZeneca insurance fraud case can be said to be the most shocking event caused by multinational pharmaceutical companies in China ...
- Source: drugdu
- 185
- December 6, 2024
“China’s Multi-Antibody Star” launches IPO

Recently, “China’s multi-antibody star” Welly Zhibo Biotech submitted a prospectus to the Hong Kong Stock Exchange, intending to go public on the main board of Hong Kong through an IPO. This biotech, founded in 2012, had just completed a large NewCo-style BD and also completed a C+ round of financing in November. The latest post-investment valuation has exceeded 3 billion yuan. The latest valuation is over 3 billion. Welly Zhibo’s CEO is Dr. Kang Xiaoqiang, who studied for his master’s degree at Tongji Medical College, and completed his doctoral and postdoctoral studies in the United States. Later, he joined a biotech called ImClone Systems, which became famous for the development of the EGFR monoclonal antibody Erbitux. The drug was launched in 2004, with peak sales of more than 2 billion US dollars, and Kangbo participated in the development and launch of the drug. In 2008, ImClone Systems was acquired by ...
- Source: drugdu
- 334
- December 6, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.